Recent research suggests that in the breast tumor environment, tumor-infiltrating T lymphocytes (TILs) secrete IL-17A, to activate the MAPK pathway, promoting proliferation and resistance to conventional chemotherapeutic agents (27). Here, IL17A is linked to neoplasm.